Liver Transplantation for Hepatocellular Carcinoma: a Proposal for Including Preoperative Serological Indicators Improves the Milan Criteria Expanded

Overview

Journal Transl Gastroenterol Hepatol

Publisher AME Publishing Company

Specialty Gastroenterology

Date 2024 Nov 6

PMID 39503026

Authors

Ning Jiao

Cheng Yan

Li He

Hai-Long Jin

Shuang Oiu

Chao Li

Zhi-Sheng Zheng

Bin Lu

Feng-Dong Wu

Yang Yang

Xin-Guo Chen

Qing Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Liver transplantation (LT) is the most effective and radical treatment for hepatocellular carcinoma (HCC). Most LT criteria are based on the morphological characteristics of tumors, which are not enough to predict the risk of tumor recurrence. It is found that some serological biomarkers can predict tumor recurrence and may be a good indicator for selecting suitable HCC patients for LT. This article aims to evaluate the predictive effect of preoperative serological indicators on long-term overall survival (OS) and tumor recurrence-free survival (TFS) of patients with HCC after LT, and to explore its significance for expanding the Milan criteria.

Methods: Clinical data of 253 patients after LT in HCC were collected retrospectively. The receiver operating characteristic curve was used to calculate the best cut-off value. χ test was used to analyze the correlation between preoperative serological indicators and tumor pathological features. Univariate and multivariate analyses were used to analyze the risk factors affecting the OS and TFS rates and the predictive values of different LT criteria were compared. Nomogram model was used to predict the OS and TFS rates of patients exceeding Milan criteria.

Results: Independent risk factors for poor OS and TFS rates were alpha-fetoprotein (AFP) >200 ng/mL, gamma-glutamyl transpeptidase (GGT) >80 IU/L, total tumor diameter (TTD) >8 cm and microsatellite lesions. Nomogram model showed patients beyond Milan criteria had better survival when AFP ≤200 ng/mL and GGT ≤80 IU/L or AFP >200 ng/mL, GGT ≤80 IU/L and TTD ≤8 cm. According to Milan criteria, AFP, GGT and TTD, Milan-AFP-GGT-TTD (M-AGT) criteria was established. There was no significant difference in OS and TFS rates among patients in M-AGT, Milan, Hangzhou, Malaya and the University of California at San Francisco (UCSF) criteria.

Conclusions: Preoperative serological indicators AFP and GGT can effectively predict long-term OS and TFS in HCC patients after LT. Establishing M-AGT criteria based on serological indicators is helpful to supplement the Milan criteria.

References

Xia J, Song P, Sun Z, Sawakami T, Jia M, Wang Z . Advances of diagnostic and mechanistic studies of γ-glutamyl transpeptidase in hepatocellular carcinoma. Drug Discov Ther. 2016; 10(4):181-7. DOI: 10.5582/ddt.2016.01052. View

Costentin C, Bababekov Y, Zhu A, Yeh H . Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation?. Hepatology. 2018; 69(3):1324-1336. DOI: 10.1002/hep.30278. View

Lee S, Hwang S, Moon D, Ahn C, Kim K, Sung K . Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008; 14(7):935-45. DOI: 10.1002/lt.21445. View

Song P, Cai Y, Tang H, Li C, Huang J . The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. Biosci Trends. 2017; 11(4):389-398. DOI: 10.5582/bst.2017.01202. View

Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X . Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2019; 26(2):599-603. DOI: 10.1007/s12253-019-00585-5. View

Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G . Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2016; 66(3):552-559. DOI: 10.1016/j.jhep.2016.10.038. View

Fu S, Zhao Q, Ji F, Chen M, Wu L, Ren Q . Elevated Preoperative Serum Gamma-glutamyltranspeptidase Predicts Poor Prognosis for Hepatocellular Carcinoma after Liver Transplantation. Sci Rep. 2016; 6:28835. PMC: 4933871. DOI: 10.1038/srep28835. View

Fu J, Li Y, Li Z, Li N . Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma. Biosci Rep. 2018; 38(5). PMC: 6172421. DOI: 10.1042/BSR20180044. View

Gunsar F . Liver Transplantation for Hepatocellular Carcinoma Beyond the Milan Criteria. Exp Clin Transplant. 2017; 15(Suppl 2):59-64. DOI: 10.6002/ect.TOND16.L16. View

10.

Mazzaferro V, Llovet J, Miceli R, Bhoori S, Schiavo M, Mariani L . Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2008; 10(1):35-43. DOI: 10.1016/S1470-2045(08)70284-5. View

11.

Tran B, Moris D, Markovic D, Zaribafzadeh H, Henao R, Lai Q . Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium. Liver Transpl. 2023; 29(7):683-697. DOI: 10.1097/LVT.0000000000000145. View

12.

Mehta N, Bhangui P, Yao F, Mazzaferro V, Toso C, Akamatsu N . Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020; 104(6):1136-1142. DOI: 10.1097/TP.0000000000003174. View

13.

Li Z, Li Z, Li C, Fang J, Li X, Zhao Y . Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection. Aliment Pharmacol Ther. 2020; 52(11-12):1762-1763. DOI: 10.1111/apt.16124. View

14.

Costentin C, Pinero F, Degroote H, Notarpaolo A, Boin I, Boudjema K . R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. JHEP Rep. 2022; 4(5):100445. PMC: 8961219. DOI: 10.1016/j.jhepr.2022.100445. View

15.

Tsutsumi M, Sakamuro D, Takada A, Zang S, Furukawa T, Taniguchi N . Detection of a unique gamma-glutamyl transpeptidase messenger RNA species closely related to the development of hepatocellular carcinoma in humans: a new candidate for early diagnosis of hepatocellular carcinoma. Hepatology. 1996; 23(5):1093-7. DOI: 10.1002/hep.510230524. View

16.

Singh S, Hoque S, Zekry A, Sowmya A . Radiological Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: A Review. J Med Syst. 2023; 47(1):73. PMC: 10335966. DOI: 10.1007/s10916-023-01968-7. View

17.

Jing W, Peng R, Zhu M, Lv S, Jiang S, Ma J . Differential Expression and Diagnostic Significance of Pre-Albumin, Fibrinogen Combined with D-Dimer in AFP-Negative Hepatocellular Carcinoma. Pathol Oncol Res. 2019; 26(3):1669-1676. DOI: 10.1007/s12253-019-00752-8. View

18.

Yao F, Ferrell L, Bass N, Watson J, Bacchetti P, Venook A . Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33(6):1394-403. DOI: 10.1053/jhep.2001.24563. View

19.

Guo C, Liang H, Yuan W, Qin Y . Analysis on the value of soluble intercellular adhesion molecule-1 (sICAM-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index (APRI) in predicting the prognostic survival of patients with primary liver cancer after.... Ann Palliat Med. 2021; 10(4):4760-4767. DOI: 10.21037/apm-21-749. View

20.

Ince V, Akbulut S, Otan E, Ersan V, Karakas S, Sahin T . Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria. J Gastrointest Cancer. 2020; 51(3):998-1005. DOI: 10.1007/s12029-020-00424-w. View